A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2007/2008 when administered to adult and elderly subjects
- Conditions
- o medical condition, healthy volunteers will be recruited into clinical trial for annual approval of influenza vaccine with the new strain composition according WHO and EMEA recommendation and CPMP criteria (CPMP/BWP/214/96)
- Registration Number
- EUCTR2007-001403-38-DE
- Lead Sponsor
- ovartis Vaccines and Diagnostics GmbH & Co. KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Subjects eligible for enrollment into this study are male and female adults who are
1. = 18 years of age, mentally competent, willing and able to give informed consent prior to study entry
2. available for all the visits scheduled in the study and able to comply with all study requirements
3. in good health as determined by:
- medical history
- physical examination
- clinical judgment of the investigator
4. Written informed consent must be obtained from all the subjects before enrollment in the study after the nature of the study has been explained.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Subjects are not to be enrolled into the study if at least one of the following criteria is fulfilled:
1. Any serious chronic or acute disease such as:
a. Cancer (leukemia, lymphomas, neoplasm), except for benign or localized skin cancer and non-metastatic prostate cancer not presently treated with chemotherapy
b. Congestive heart failure
c. Advanced arteriosclerotic disease
d. Chronic obstructive pulmonary disease (COPD) requiring oxygen therapy and/or acute exacerbation of a COPD within the last 14 days.
e. Autoimmune disease (including rheumatoid arthritis), if under immunosuppressive therapy (see below)
f. Insulin dependent diabetes mellitus
g. Acute or progressive hepatic disease
h. Acute or progressive renal disease
i. Severe neurological or psychiatric disorder
2. History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g. to ovalbumin, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin).
3. Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting for example from:
a. Receipt of immunosuppressive therapy (chronic therapy with immunosuppressive drugs, any parenteral or oral corticosteroid (substitution dose in case of absence of suprarenal function allowed) or cancer chemotherapy/radiotherapy) within the last 2 months and for the full length of the study,
b. Receipt of immunostimulants,
c. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study,
d. Suspected or known HIV infection or HIV-related disease.
4. Known or suspected history of drug or alcohol abuse.
5. Bleeding diathesis or receive anticoagulants of the coumarin type.
6. Women who are pregnant or woman of childbearing potential unwilling to practice acceptable contraception for the duration of the study (21 days).
7. Influenza vaccination or laboratory confirmed influenza within the last 6 months and more than one influenza vaccination within the past 12 months
8. Immunization with any other vaccine and/or any investigational vaccine four weeks prior to study start
9. Any significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the last 7 days.
10. Fever (i.e. body temperature =38.0°C) within the past 3 days prior to study entry.
11. Simultaneous participation in another clinical study.
12. Any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method